Oncolytic Virus Panels to Overcome Tumor Resistance and Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing oncolytic virus therapies face challenges such as individual variability of cancer cells, development of antiviral adaptive immunity, and resistance of cancer cells to single virus strains, leading to unpredictable therapeutic responses and potential relapses.
Innovation Solution
Administering a panel of oncolytic viruses, either simultaneously or sequentially, that differ in antigenic structure and host-cell surface receptor requirements to enhance therapeutic efficacy and overcome resistance, combined with methods to optimize virus replication in cancer cells and reduce neutralization by antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If a single oncolytic virus strain is used for cancer treatment, then the treatment approach is simple and cost-effective, but cancer cells develop resistance and antiviral adaptive immunity leads to treatment failure
Solution Approach 1:
The treatment approach is segmented into multiple virus strains administered either simultaneously or sequentially. Each virus strain targets different cancer cell characteristics or uses different entry mechanisms, preventing resistance development while maintaining manageable treatment complexity through modular administration schedules
Solution Approach 2:
Multiple oncolytic virus strains are combined into a composite therapeutic regimen. This composite approach leverages the complementary properties of different viruses (e.g., different receptor requirements, replication mechanisms) to achieve broader cancer cell killing while reducing the development of adaptive immunity
2Reliability
If multiple oncolytic viruses are administered simultaneously or sequentially, then therapeutic efficacy is enhanced and resistance is overcome, but treatment complexity and administration burden increase
Solution Approach 1:
The complex multi-virus treatment is segmented into discrete administration cycles that can be managed systematically. Each virus strain is administered in defined time intervals or combined in controlled ratios, breaking down the complexity into manageable steps while maintaining enhanced therapeutic efficacy
Solution Approach 2:
Multiple virus administrations are organized into periodic cycles with defined intervals. This periodic structure allows the immune system to respond between doses while maintaining continuous pressure on cancer cells, balancing enhanced efficacy with administrable rhythm
3Productivity
If virus replication is optimized in cancer cells, then oncolytic activity is enhanced, but neutralization by antiviral antibodies increases
Solution Approach 1:
The viral genome is segmented into multiple strains with different antigenic profiles. This segmentation ensures that while each virus replicates efficiently in cancer cells, the collective diversity reduces the impact of any single antibody response, as antibodies against one strain do not necessarily neutralize other strains
Solution Approach 2:
Viral replication parameters are optimized for cancer cell specificity while maintaining antigenic diversity. By adjusting replication kinetics, viral load, and strain composition, the system achieves high oncolytic activity while distributing antibody neutralization pressure across multiple viral variants
Data Source
Figure 1A~1B
Figure 1C
Figure 2
AI summary
Methods of inhibiting or reducing tumor growth are disclosed. A composition containing at least one selected oncolytic virus is administered within a tumor of a patient. The virus kills cancerous cells and induces a systemic and lasting anti-tumor immunity that is also compatible with other cancer treatments. Also disclosed are methods of creating synthetic viruses for targeting cancerous tumors.